Reduction of calprotectin and phosphate during testosterone therapy in aging men: a randomized controlled trial

Autor: Lars Pedersen, Louise Lehman Christensen, Susanne Møller Pedersen, Marianne Andersen
Rok vydání: 2016
Předmět:
0301 basic medicine
Fibroblast growth factor 23
Male
Aging
Endocrinology
Diabetes and Metabolism
Testosterone/administration & dosage
Parathyroid hormone
chemistry.chemical_compound
Phosphates/blood
0302 clinical medicine
Endocrinology
FGF23
Risk Factors
Testosterone
Klotho
Middle Aged
Prognosis
Aging/drug effects
Testosterone therapy
Androgens
Female
medicine.medical_specialty
medicine.drug_class
Phosphate
030209 endocrinology & metabolism
Placebo
Phosphates
03 medical and health sciences
Double-Blind Method
Internal medicine
medicine
Humans
Aged
Calprotectin
Creatinine
business.industry
Testosterone (patch)
Androgen
Androgens/administration & dosage
Fibroblast Growth Factor-23
030104 developmental biology
chemistry
Leukocyte L1 Antigen Complex/blood
business
Leukocyte L1 Antigen Complex
Biomarkers
Follow-Up Studies
Zdroj: Pedersen, L, Christensen, L L, Pedersen, S M & Andersen, M 2017, ' Reduction of calprotectin and phosphate during testosterone therapy in aging men : a randomized controlled trial ', Journal of Endocrinological Investigation, vol. 40, no. 5, pp. 529-538 . https://doi.org/10.1007/s40618-016-0597-3
ISSN: 1720-8386
Popis: Objectives: To investigate the effect of testosterone treatment on biomarkers calprotectin, fibroblast growth factor 23 (FGF23), soluble Klotho, phosphate, calcium, parathyroid hormone, creatinine and estimated glomerular filtration rate. Design: Randomized, double-blinded, placebo-controlled study. Setting: Odense Androgen Study—the effect of Testim and training in hypogonadal men. Participants: Men aged 60–78 years old with a low normal concentration of free of bioavailable testosterone 94 cm recruited from 2008 to 2009 (N = 48) by advertisement. Intervention: Participants were randomized to receive 5–10 g gel/50–100 mg testosterone (Testim®, Ipsen, France) or 5–10 g gel/placebo. Results: The plasma levels of calprotectin and phosphate were significantly reduced in the group receiving testosterone therapy (gel) compared to the placebo group (p
Databáze: OpenAIRE
Externí odkaz: